Catalog No.
DHC29903
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-nd
Clonality
Monoclonal
Target
CD221, Insulin-like growth factor 1 receptor, IGF1R, Insulin-like growth factor I receptor, IGF-I receptor
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P08069
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
RO4858696-000, CAS: 1036734-93-6
Clone ID
Teprotumumab
Teprotumumab: First Approval, PMID: 32157641
Teprotumumab for the Treatment of Active Thyroid Eye Disease, PMID: 31971679
Teprotumumab for Thyroid-Associated Ophthalmopathy, PMID: 28467880
Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy, PMID: 32429706
Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy, PMID: 33391187
Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition, PMID: 32040069
Teprotumumab for the treatment of thyroid eye disease, PMID: 32707005
Teprotumumab for Thyroid Eye Disease, PMID: 32205652
Teprotumumab for Active Thyroid Eye Disease, PMID: 32402171
Teprotumumab for Active Thyroid Eye Disease, PMID: 32402170
Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression, PMID: 33221815
Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease, PMID: 33172865
[Teprotumumab for thyroid-associated ophthalmopathy : OPTIC], PMID: 33025123
Antibodies to watch in 2020, PMID: 31847708
Teprotumumab for Active Thyroid Eye Disease. Reply, PMID: 32402172
Teprotumumab: a disease modifying treatment for graves' orbitopathy, PMID: 32636936
Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy, PMID: 32088116
Treatment of Graves' ophthalmopathy, PMID: 33069387
Teprotumumab in Clinical Practice: Recommendations and Considerations From the OPTIC Trial Investigators, PMID: 33417417
Teprotumumab, PMID: 34292697
Teprotumumab (Tepezza): from the discovery and development of medicines to USFDA approval for active thyroid eye disease (TED) treatment, PMID: 33481154
Teprotumumab, PMID: 33886177
Early experience with teprotumumab for chronic thyroid eye disease, PMID: 32462101
[Teprotumumab - selective IGF-1-receptor blockade improves significantly endocrine opthalmopathy in Basedow's disease], PMID: 32392608
Teprotumumab for Dysthyroid Optic Neuropathy: Early Response to Therapy, PMID: 32976335
Current and Emerging Treatment Strategies for Graves' Orbitopathy, PMID: 30659423
Antibodies to watch in 2019, PMID: 30516432
Medical treatment in thyroid eye disease in 2020, PMID: 32447327
Ototoxicity and Teprotumumab, PMID: 34448414
New insights into the pathogenesis and nonsurgical management of Graves orbitopathy, PMID: 31889140
Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis, PMID: 30575804
A New Era in the Treatment of Thyroid Eye Disease, PMID: 31377284
Current and Future Treatments for Graves' Disease and Graves' Ophthalmopathy, PMID: 30286486
Teprotumumab for Optic Neuropathy in Thyroid Eye Disease, PMID: 33270090
Teprotumumab for thyroid eye disease: early response is not required for benefit, PMID: 34183792
Resolution of pretibial myxedema with teprotumumab in a patient with Graves disease, PMID: 33294564
Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies, PMID: 33930408
Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy, PMID: 30215690
Teprotumumab Treatment for Thyroid-Associated Ophthalmopathy, PMID: 33511083
Graves' disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy, PMID: 32059832
Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy, PMID: 27346786
[Update Graves' disease 2019], PMID: 30703831
Current Understanding of the Progression and Management of Thyroid Associated Orbitopathy: A Systematic Review, PMID: 31823232
Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring, PMID: 34085994
Graves’ Disease: Complications, PMID: 25905406
Teprotumumab for chronic thyroid eye disease, PMID: 34060414
Immunotherapies for thyroid eye disease, PMID: 31356255
Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes, PMID: 24878056
Novel therapies for thyroid autoimmune diseases: An update, PMID: 31813786
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials, PMID: 33865501
For research use only. Not for human or drug use.
